End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.71 CNY | -3.24% | +1.75% | +23.16% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.16% | 2.98B | D- | ||
+45.82% | 754B | C+ | ||
+40.95% | 630B | B | ||
-6.16% | 352B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 298B | C+ | ||
+18.45% | 250B | B+ | ||
+11.88% | 217B | B- | ||
-0.78% | 216B | A+ | ||
+5.90% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002773 Stock
- Ratings Chengdu Kanghong Pharmaceutical Group Co., Ltd